LYTIR

Company · AGMB

AgomAb Therapeutics NV

Nasdaq's symbol directory lists AGMB on Nasdaq as “AgomAb Therapeutics NV - ADRs representing one common share.”: an American depositary receipt, a certificate traded in the US for shares of a foreign company.

In the 12 months to Nov 8, 2026: insiders bought on 8 occasions ($503K).

All insider filings at the SEC · Appeared in No. 35, No. 34, No. 33, No. 32, No. 31, No. 30, No. 29, No. 22

Insider purchases and sales, by month (last 12 months)Insider purchases: $503K in total; Insider sales: $0 in total.Oct: Insider purchases $400KNov: Insider purchases $104KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $503KInsider sales below: $0
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Epstein David R bought on 5 days latest Nov 5, 2026 bought $323K
  2. Knotnerus Tim Jasper, Chief Executive Officer bought on 2 days latest Oct 6, 2026 bought $94K
  3. Kemula Pierre Thadee Victor, Chief Financial Officer bought on 1 day latest Oct 6, 2026 bought $86K
Every trade (8)
  1. BUYEpstein David R bought Nov 5, 2026 15,000 shares 3 legs combined filing $104K
  2. BUYEpstein David R bought Oct 21, 2026 10,000 shares 2 legs combined filing $89K
  3. BUYEpstein David R bought Oct 8, 2026 5,000 shares filing $44K
  4. BUYKemula Pierre Thadee Victor, Chief Financial Officer bought Oct 6, 2026 10,000 shares 3 legs combined filing $86K
  5. BUYEpstein David R bought Oct 6, 2026 5,000 shares filing $44K
  6. BUYKnotnerus Tim Jasper, Chief Executive Officer bought Oct 6, 2026 5,000 shares filing $44K
  7. BUYKnotnerus Tim Jasper, Chief Executive Officer bought Oct 5, 2026 6,000 shares filing $51K
  8. BUYEpstein David R bought Oct 5, 2026 5,000 shares filing $43K

Sources: SEC EDGAR (Forms 4 and 144) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.